Kazuyuki Yoshizaki

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.

Journal: Frontiers in immunology

Published: November 14, 2024

Immunology and targeted therapy in Castleman disease.

Immunology and targeted therapy in Castleman disease.

Journal: Expert review of clinical immunology

Published: May 24, 2024

Predictive biomarkers of COVID-19 prognosis identified in Bangladesh patients and validated in Japanese cohorts.

Predictive biomarkers of COVID-19 prognosis identified in Bangladesh patients and validated in Japanese cohorts.

Journal: Scientific reports

Published: November 01, 2023

Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.

Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.

Journal: Nature communications

Published: August 30, 2022

Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein.

Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein.

Journal: Scientific reports

Published: February 02, 2022

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19.

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19.

Journal: Frontiers in medicine

Published: July 01, 2021

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.

Journal: American journal of hematology

Published: July 01, 2021

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Journal: Blood advances

Published: September 03, 2020

IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.

IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.

Journal: Modern rheumatology

Published: November 15, 2018

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.

Journal: Modern rheumatology

Published: October 05, 2018

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Journal: Blood

Published: July 11, 2018

The Role of Interleukin-6 in Castleman Disease.

The Role of Interleukin-6 in Castleman Disease.

Journal: Hematology/oncology clinics of North America

Published: November 22, 2017

Showing 1-12 of 23

Last Updated: 09/26/2026